Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction: A Prospective, Multicenter, Pragmatic Randomized Controlled Real-World Study

NCT07153744 is registered in ClinicalTrials.gov with Shanghai Hutchison Pharmaceuticals Limited as lead sponsor.

NCT NCT07153744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07153744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction: A Prospective, Multicenter, Pragmatic Randomized Controlled Real-World Study
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited
Phase
Phase 4
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 31, 2029
Enrollment
9,588 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction (ami), percutaneous coronary intervention (pci)